Th only thing that is going to move this stock in a consistent fashion is Eli 200 approval and institututional investors- and there we be institutional investors at the R&R conference.
Institutions and competitor Pharmas will have their prime investigators at $ELTP R&R presentation in order to decide their strategy direction. We will have to wait until then for the $ELTP PPS activity.